Cardurion

Cardurion

Private
Burlington, MassachusettsHealthcare & Life Scienceshttps://www.cardurion.com

Last Round

Series B

7/16/2024

Total Funding Raised

$631.8M

Company Overview

Cardurion Pharma is a biotechnology company focused on developing innovative cardiovascular therapeutics aimed at treating heart diseases and preventing related complications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

heart failure drugsPDE9 inhibitorscardiovascular therapeuticsfirst-in-class therapeuticsclinical-stage biotechdrug discoveryCaMKII inhibitorbiopharmasmall-molecule therapeuticsheart failure with preserved ejection fractionHFpEFheart failure with reduced ejection fractionHFrEFrare cardiovascular diseasesarrhythmia treatmentcatecholaminergic polymorphic ventricular tachycardiaCPVT

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cardurion Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Cardurion Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series B7/16/2024
Series A Extension12/30/2022
Corporate Funding10/27/2021
Series A11/20/2019
Seed4/4/2017

Key People

Founding team and executive leadership

Peter Lawrence

CEO And President

Executive Team

Elizabeth Radcliffe

Chief Financial Officer

Executive Team

Marcia Moore

Chief Operating Officer

Executive Team

Cardurion Investors

Notable investors and investment history

InvestorRounds
Owl Rock Capital GroupSeries B
Bain Capital Life SciencesSeries B, Corporate Funding
Farallon Capital ManagementSeries B
GVSeries B
Digitalis VenturesSeries B
New Enterprise Associates (NEA)Series B
Millennium ManagementSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 20, 2025

    Karen Lewis joins as Chief People Officer.

  • Jan 8, 2025

    Charlotte Newman joins as Chief Business Officer.

Cardurion Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Cardurion Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Cardurion's valuation, stock price, and market status.

Firmographic Details

HeadquartersBurlington, Massachusetts
Employee Range83
Year Founded2017
Last Funding7/16/2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







DisclaimerAll investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.